KEY TAKEAWAYS Kohl's stock is plummeting 17% in premarket trading after it reported weaker-than-expected third-quarter ...

Kohl's expects sales to be down 7-8% for the year, which is the third quarter in a row the company has changed its ...

Kohl’s Corp. shares plunged 16.6% in premarket trading on Tuesday after the company cut its full-year sales outlook, ...

Ashley Buchanan, CEO of Michaels Companies will become the new CEO on Jan. 15, Kohl’s announced. He has been CEO of Michaels ...

Is now the time to buy Kohl's? Find out by accessing our full research report, it’s free. Tom Kingsbury, Kohl’s chief executive officer, said “Our third quarter results did not meet our expectations ...

Kohl's reported disappointing Q3 earnings as sales in key segments lagged expectations, prompting a downward revision of its ...

Kohl’s (KSS) slid over -4% in pre-market trading after the company said in a statement that CEO Tom Kingsbury will resign effective January 15th, 2025. Chevron (CVX) gained more than +1% in pre-market ...

Kohl’s Corporation’s outgoing CEO Tom Kingsbury said in a Tuesday media release that third quarter results did not meet ...

Kohl’s Corporation is reporting that company CEO Tom Kingsbury plans to step down as CEO, effective January 15, 2025. He will ...

The Dow Jones dropped on the stock market today after President-elect Donald Trump's tariff threat on China, Canada and ...

Kohl’s stock tanks after yet another sales miss, as the retailer’s core apparel and shoes businesses remain weak.

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.